These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 26567561

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
    Dang TO, Ogunniyi A, Barbee MS, Drilon A.
    Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
    [Abstract] [Full Text] [Related]

  • 4. Emerging drugs for squamous cell lung cancer.
    Cheng H, Shcherba M, Kandavelou K, Liang Y, Liu H, Perez-Soler R.
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):149-60. PubMed ID: 25557559
    [Abstract] [Full Text] [Related]

  • 5. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G, Salvati V, Mottolese M, Visca P, Gallo E, Fecchi K, Pilozzi E, Duranti E, Policicchio E, Tartaglia M, Milella M, De Maria R, Eramo A.
    Cell Death Dis; 2015 Aug 06; 6(8):e1850. PubMed ID: 26247735
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
    Sacher AG, Gandhi L.
    JAMA Oncol; 2016 Sep 01; 2(9):1217-22. PubMed ID: 27310809
    [Abstract] [Full Text] [Related]

  • 8. A decade of advances in treatment for advanced non-small cell lung cancer.
    Gettinger S, Lynch T.
    Clin Chest Med; 2011 Dec 01; 32(4):839-51. PubMed ID: 22054890
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, Murray N, Lam WL, Ling V, Lam S, Gout PW, Wang Y.
    J Thorac Oncol; 2013 Feb 01; 8(2):161-70. PubMed ID: 23287853
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Squamous non-small cell lung cancer as a distinct clinical entity.
    Oliver TG, Patel J, Akerley W.
    Am J Clin Oncol; 2015 Apr 01; 38(2):220-6. PubMed ID: 25806712
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
    Casaluce F, Sgambato A, Sacco PC, Palazzolo G, Maione P, Rossi A, Ciardiello F, Gridelli C.
    Expert Opin Emerg Drugs; 2014 Dec 01; 19(4):557-69. PubMed ID: 25253438
    [Abstract] [Full Text] [Related]

  • 16. Onartuzumab in lung cancer: the fall of Icarus?
    Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F.
    Expert Rev Anticancer Ther; 2015 May 01; 15(5):487-9. PubMed ID: 25818471
    [Abstract] [Full Text] [Related]

  • 17. New antiangiogenetic agents and non-small cell lung cancer.
    Gridelli C, Rossi A, Maione P.
    Crit Rev Oncol Hematol; 2006 Oct 01; 60(1):76-86. PubMed ID: 16843002
    [Abstract] [Full Text] [Related]

  • 18. Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.
    Riess JW, Wakelee HA.
    Clin Adv Hematol Oncol; 2012 Apr 01; 10(4):226-34. PubMed ID: 22706483
    [Abstract] [Full Text] [Related]

  • 19. Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
    Pluquet E, Cadranel J, Legendre A, Faller MB, Souquet PJ, Zalcman G, Perol M, Fraboulet G, Oliveiro G, De Fraipont F, Quoix E, Lantuejoul S, Milleron B, Moro-Sibilot D.
    J Thorac Oncol; 2010 Apr 01; 5(4):491-6. PubMed ID: 20195171
    [Abstract] [Full Text] [Related]

  • 20. Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.
    Sacco PC, Maione P, Rossi A, Sgambato A, Casaluce F, Palazzolo G, Gridelli C.
    Expert Rev Respir Med; 2015 Jun 01; 9(3):245-54. PubMed ID: 25797462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.